- Home
- MBRX vs EDSA Comparison
MBRX vs EDSA Comparison
Compare MBRX & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBRX | EDSA |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 12.3M |
| IPO Year | 2016 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MBRX | EDSA |
|---|---|---|
| Price | $2.68 | $0.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $105.50 | $13.00 |
| AVG Volume (30 Days) | 97.5K | ★ 131.9K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $0.94 |
| 52 Week High | $7.98 | $2.95 |
Technical Indicators
Market Signals| Indicator | MBRX | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 31.40 | 24.13 |
| Support Level | $4.03 | $0.94 |
| Resistance Level | $5.30 | $1.18 |
| Average True Range (ATR) | 0.36 | 0.15 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 4.36 | 0.00 |
Price Performance
Historical ComparisonAbout MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.